Assetmark Inc. Purchases 19,844 Shares of Lantheus Holdings, Inc. $LNTH

Assetmark Inc. lifted its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 20.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 118,503 shares of the medical equipment provider’s stock after purchasing an additional 19,844 shares during the period. Assetmark Inc. owned 0.17% of Lantheus worth $6,078,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the business. Parkside Financial Bank & Trust increased its position in Lantheus by 20.2% in the 2nd quarter. Parkside Financial Bank & Trust now owns 1,264 shares of the medical equipment provider’s stock worth $103,000 after buying an additional 212 shares during the period. First National Advisers LLC grew its stake in shares of Lantheus by 0.8% in the second quarter. First National Advisers LLC now owns 27,995 shares of the medical equipment provider’s stock worth $2,292,000 after acquiring an additional 213 shares during the last quarter. United Community Bank increased its position in Lantheus by 15.6% during the third quarter. United Community Bank now owns 1,815 shares of the medical equipment provider’s stock worth $93,000 after acquiring an additional 245 shares during the period. State of New Jersey Common Pension Fund D increased its position in Lantheus by 1.0% during the second quarter. State of New Jersey Common Pension Fund D now owns 25,197 shares of the medical equipment provider’s stock worth $2,063,000 after acquiring an additional 249 shares during the period. Finally, Elevation Point Wealth Partners LLC acquired a new position in Lantheus during the 2nd quarter valued at $26,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Price Performance

Shares of Lantheus stock opened at $69.38 on Tuesday. The firm has a market cap of $4.60 billion, a P/E ratio of 29.15 and a beta of -0.08. The firm’s 50-day simple moving average is $66.44 and its 200-day simple moving average is $59.37. Lantheus Holdings, Inc. has a twelve month low of $47.25 and a twelve month high of $111.29. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.49 and a current ratio of 2.67.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Weiss Ratings upgraded shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, January 6th. Truist Financial increased their target price on shares of Lantheus from $80.00 to $82.00 and gave the company a “buy” rating in a research note on Thursday, December 18th. Finally, Mizuho lifted their target price on Lantheus from $60.00 to $72.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 17th. Five research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $78.00.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.